Results 101 to 110 of about 5,730 (206)

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. [PDF]

, 2013
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter ...
Afdhal, NH, Castera, L, Church, DR, Dee, L, Graham, C, Jacobson, IM, Litwin, AH, Mehta, SH, Muir, A, New Paradigm of HCV Therapy Meeting Participants, Poynard, T, Razavi, H, Schooley, RT, Sulkowski, MS, Talal, AH, Thomas, DL, Ward, JW, Zeuzem, S   +17 more
core   +2 more sources

Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease [PDF]

, 2016
Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis.
Maan, R. (Raoel), Meer, A.J.P. (Adriaan) van der   +1 more
core   +5 more sources

Avances en hepatitis C

Revista del Hospital Italiano de Buenos Aires
La hepatitis C es la principal causa de hepatitis crónica, cirrosis y cáncer de hígado, así como la indicación más común de trasplante hepático en la Argentina y muchos otros países.
Ezequiel Mauro, Sebastián Marciano, Omar Galdame, Adrián Gadano   +3 more
doaj  

Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review

Canadian Journal of Gastroenterology and Hepatology, 2014
Between 2001 and 2011, the standard of care for chronic hepatitis C virus (HCV) infection was a combination of pegylated interferon (PEGIFN) and ribavirin (RBV).
Alan Hoi Lun Yau, Eric M Yoshida
doaj   +1 more source

Simeprevir

Reactions Weekly, 2015
  +6 more sources

Markedly Improved Glycemic Control in Poorly Controlled Type 2 Diabetes following Direct Acting Antiviral Treatment of Genotype 1 Hepatitis C

Case Reports in Hepatology, 2016
Type 2 diabetes mellitus (T2DM) is often associated with hepatitis C virus (HCV) infection. Successful HCV treatment may improve glycemic control and potentially induce remission of T2DM. We report a case of an obese 52-year-old woman with mixed genotype
Raymond Anthony Pashun, Nicole T. Shen, Arun Jesudian   +2 more
doaj   +1 more source

Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil

Brazilian Journal of Infectious Diseases
Background This study aimed to evaluate the clinical effectiveness in terms of sustained virological response and tolerability of available second generation direct-acting antivirals in Brazilian patients.
Vinicius Lins Ferreira, Helena Hiemisch Lobo Borba, Astrid Wiens, Maria Lucia Alves Pedroso, Vanessa Ferreira de Camargo Radunz, Cláudia Alexandra Pontes Ivantes, Aline Satie Oba Kuniyoshi, Roberto Pontarolo   +7 more
doaj   +1 more source

Perfil dos primeiros pacientes com Hepatite C tratados com SIMEPREVIR na Bahia e os desfechos desta terapia

Jornal de Assistência Farmacêutica e Farmacoeconomia
Introdução: A infecção pelo vírus da hepatite C é um problema de saúde pública, afeta 2,3 milhões de pessoas no Brasil e é responsável por 75% dos óbitos por hepatites virais.
Jane Meire Magalhães Carneiro, Rosemeire Dourado Costa Fernandes, Mila Palma Pacheco, Maria Gleide Cunha Rodrigues, Christiane Vianna Cavalcante, Jorge Viana dos Santos, Marcia Cristina da Silva Ribeiro, Suzana Márcia Nascimento   +7 more
doaj   +1 more source

A simeprevir-inducible molecular switch for the control of cell and gene therapies. [PDF]

Nat Commun, 2023
Chin SE, Schindler C, Vinall L, Dodd RB, Bamber L, Legg S, Sigurdardottir A, Rees DG, Malcolm TIM, Spratley SJ, Granéli C, Sumner J, Tigue NJ.   +12 more
europepmc   +1 more source

History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C [PDF]

, 2015
The development of antiviral drugs is a very complex process. Currently, around 50 drugs have been approved for human use against viruses such as HSV, HIV-1, the cytomegalo virus, the influenza virus, HBV and HCV.
Barrera Saldaña, Hugo Alberto, Bryan Marrugo, Owen Lloyd, Ramos Jiménez, Javier, Rivas Estilla, Ana María, Rojas Martínez, Augusto, Vidaltamayo, Román   +5 more
core